1. St-Petersburg State Pediatric Medical University (St. Petersburg, Russian Federation)
2. First Pavlov St-Petersburg State Medical University (St. Petersburg, Russian Federation)
3. Science Research Institute (St. Petersburg, Russian Federation)
4. Elizavetinskaya hospital (St. Petersburg, Russian Federation)

Keywords:Helicobacter pylori,obesity,metabolic syndrome

Abstract:The review of the modern researches about a role of Helicobacter pylori (as one of the most famous and widespread bacterial agents) in pathogenesis of a metabolic syndrome is presented in article. However results of scientific works are sometimes contradictory that dictates need of make new further researches for specification of features of influence of Helicobacter pylori in formation of different components of a metabolic syndrome.

• References total 60 ⇓ :: .
  1. Lakka H. M. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men / H. M. Lakka, D. E. Laaksonen, T. A. Lakka // JAMA. - 2002. - Vol. 4, N. 21. - P. 2709-2716.
  2. Franceschi F., Annalisa T., Teresa D. R., et al. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol 2014; 20: 12809-17.
  3. Kountouras J., Polyzos S. A., Zavos C., et al. Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology 2014; 60: 1450-1.
  4. Polyzos S. A., Kountouras J., Zavos C., Deretzi G. Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Med Hypotheses 2014; 82: 795.
  5. Vijayvergiya R., Vadivelu R. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World J Cardiol 2015; 7: 134-43.
  6. Chen T. P., Hung H. F., Chen M. K. et al. Helicobacter pylori infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study. Helicobacter 2015; 20: 184-91.
  7. Rasmi Y. Possible role of Helicobacter pylori infection via microvascular dysfunction in cardiac syndrome X / Y. Rasmi, S. Raeisi // Cardiology Journal. - 2009. - Vol. 6. - P. 585-587
  8. Pellicano R. Helicobacter pylori and insulin resistance: time to do interventional studies / R. Pellicano, M. Rizzetto // Digestive Diseases and Sciences. - 2009. - Vol.54(12). - P. 2765-2766
  9. Strachan D. P. Non-gastrointestinal consequences of Helicobacter pylori infection / D. P. Strachan // British Medical Bulletin. - 1998. - Vol. 54(1). - P. 87-93
  10. Kayar Y., Pamukçu Ö., Eroğlu H., Kalkan Erol K., Ilhan A., Kocaman O. Relationship between Helicobacter pylori Infections in Diabetic Patients and Inflammations, Metabolic Syndrome, and Complications. Int J Chronic Dis.2015;2015:290128.
  11. Martin S. S. Leptin resistance: a possible interface of inflammation and metabolism in obesity related cardiovascular disease / S. S. Martin // J Am Coll Cardiol. - 2008. - Vol.52(15). - P. 1201-1210.
  12. Успенский Ю. П., Суворов А. Н., Барышникова Н. В. Инфекция Helicobacter pylori в клинической практике. СПб.: ИнформМед, 2011. - 572 с.
  13. Stec-Michalska K., Malicki S., Michalski B. et al. Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients // World J Gastroenterol. - 2009. - Vol. 15(43). - P. 5409-5917.
  14. Konturek P. C., Cześnikiewicz-Guzik M., Bielanski W., Konturek S. L. Involvement of Helicobacter pylori infection in neuro-hormonal control of food intake// J Physiol Pharmacol. - 2006. - Vol. 57(5). - P. 67-81.
  15. Isomoto H., Ueno H., Nishi Y., Wen C. Y. / Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma // World J Gastroenterol. - 2005. - Vol. 11. - P. 1644-1648.
  16. Новоселя Н. В. Состояние пищевого статуса и адипокино-цитокинового гомеостаза у больных с хроническими заболеваниями гастропанкреатодуоденального комплекса: автореф.дис. …докт. мед.наук: 14.00.05: защищена 27.11.09 / Н. В. Новоселя. - Владикавказ, 2009. - 40 с.
  17. Suzuki H., Masaoka T., Hosoda H. et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio - a possible novel and non-invasive marker for gastric atrophy // Hepatogastroenterology. - 2004. - Vol.51(59). - P. 1249-1254.
  18. Pacifico L., Anania C., Osborn J. F. et al. Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children // Eur J Endocrinol. - 2008. - Vol.158(3). - P. 323-332.
  19. Masaoka T., Suzuki H., Imaeda H. et al. Long-term strict monitoring of plasma ghrelin and other serological markers of gastric diseases after Helicobacter pylori eradication // Hepatogastroenterology. - 2005. - Vol. 52(61). - P. 1-4.
  20. Jeffery P. L. et al. Endocrine impact of Helicobacter pylori: Focus on ghrelin and ghrelin o-acyltransferase // World J Gastroenterol. - 2011. - Vol. 17(10). - P. 1249-1260.
  21. Jang E. J., Park S. W., Park J. S. et al. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease // J Gastroenterol Hepatol. - 2008. - Vol.23(2). - P. 278-285.
  22. Li Q., Zhang J., Zhou Y., Qiao L. Obesity and gastric cancer. Front Biosci (Landmark Ed). 2012;17:2383-90.
  23. Polyzos S. A., Kountouras J., Zavos C., Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011; 16: 79-88.
  24. Eshraghian A., Hashemi S. A., Hamidian Jahromi A. et al. Helicobacter pylori infection as a risk factor for insulin resistance // Digestive Diseases and Sciences. - 2009. - Vol.54(9). - P. 1966-1970.
  25. Gen R. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation / R. Gen, M. Demir, H. Ataseven // Southern Medical Journal. - 2010. - Vol. 103(3). - P. 190-196.
  26. Dogan Z, Sarikaya M, Ergul B, Filik L. The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;159:242-5.
  27. Yang GH, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Gastric Helicobacter pylori infection associated with risk of diabetes mellitus, but not prediabetes. J Gastroenterol Hepatol 2014;29:1794-9
  28. Rekwal L, Misra SP, Misra V, Yadav RK, Srivastava A. Association of Helicobacter pylori infection with type 2 diabetes. Indian J Endocrinol Metab 2014;18:694-9
  29. Horikawa C, Kodama S, Fujihara K, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2014;106:81-7
  30. Vafaeimanesh J, Parham M, Seyyedmajidi M, Bagherzadeh M. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. Sci World J 2014;2014:391250
  31. Marietti M, Gasbarrini A, Saracco G, Pellicano R. Helicobacter pylori infection and diabetes mellitus: the 2013 state of art. Panminerva Med 2013;55:277-81
  32. Шишкин А. Н. Диабетическая гастропатия. Проблемы и решения / А. Н. Шишкин, Д. В. Кирилюк // Новые Санкт-Петербургские врачебные ведомости. - 2007. - № 1. - С. 54-58
  33. Gillum R. F. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey / R. F. Gillum // Journal of the National Medical Association. - 2004. - Vol.96(11). - P. 1470-1476
  34. Hamed S. A., Amine N. F., Galal G. M. et al. Vascular risks and complications in diabetes mellitus: the role of Helicobacter pylori infection // Journal of Stroke and Cerebrovascular Diseases. - 2008. - Vol.17(2). - P. 86-94.
  35. Diabetes mellitus and Helicobacter pylori infection / M. P. Dore, M. Bilotta, H. M. Malaty et al. // Nutrition. - 2000. - Vol.16(6). - P. 407-410.
  36. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study / B. R. Devrajani, S. Z. Shah, A. A. Soomro, T. Devrajani // International Journal of Diabetes in Developing Countries. - 2010. - Vol.30(1). - P. 22-26
  37. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori / M. Sargýn, O. Uygur-Bayramicli, H. Sargýn et al. // World Journal of Gastroenterology. - 2003. - Vol.9(5). - P. 1126-1128.
  38. Longo-Mbenza B. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics / B. Longo-Mbenza, J. Nkondi Nsenga, D. Vangu Ngoma // International Journal of Cardiology. - 2007. - Vol. 121(3). - P. 229-238.
  39. Association of Helicobacter pylori infection with elevated serum lipids / A. Laurila, A. Bloigu, S. Näyhä et al. // Atherosclerosis. - 1999. - Vol.142 (1). - P. 207-210
  40. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients / T. Kamada, J. Hata, H. Kusonoki et al. // Dig Liver Dis. - 2005. - Vol. 37. - P. 39-43
  41. Francesco Franceschi, Antonio Gasbarrini, Stergios A. Polyzos, Jannis Kountouras Extragastric Diseases and Helicobacter pylori //Helicobacter. 2015. Volume 20, Issue S 1. Pages 40-46
  42. Павлов О. Н. Носительство Helicobacter pylori как скрытый системный фактор риска // Медицинский альманах. - 2011. - № 4 (17). - С. 125-130.
  43. Nikolopoulou A., Tousoulis D., Antoniades C. et al. Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic overexpression of tumor necrosis factor alpha and vascular cells adhesion molecule-1 // Int J Cardiol. - 2008. - Vol. 130. - P. 246-250.
  44. Figura N., Franceschi F., Santucci A. et al. Extragastric Manifestations of Helicobacter pylori Infection // Helicobacter. - 2010. - Vol. 15, suppl.1. - P. 60-68.
  45. Ayada K., Yokota K., Hirai K. et al. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis // Lupus. - 2009. - Vol. 18. - P. 1154-1168.
  46. Szklo M., Ding J., Tsai M. Y. et al. Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis // J Cardiovasc Med (Hagerstown). - 2009. - Vol. 10. - P. 747-751.
  47. Honda C., Adachi K., Arima N. et al. Helicobacter pylori infection does not accellerate the age-related progression of arteriosclerosis: a 4-year follow-up study // J Gastroenterol Hepatol. - 2008. - Vol. 23. - P. 373-378.
  48. Tamer G. S., Tengiz I., Ercan E. et al. Helicobacter pylori seropositivity in patients with acute coronary syndromes // Dig Dis Sci. - 2009. - Vol. 54. - P. 1253-1256.
  49. Jha H. C., Prasad J., Mittal A. High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker // Heart Vessels. - 2008. - Vol. 23. - P. 390-396.
  50. Pasceri V., Cammarota G., Patti G. et al. Association of virulent Helicobacter pylori strains with ischemic heart disease// Circulation. - 1998. - Vol. 97(17). - P. 1675-1679.
  51. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque // Journal of Physiology and Pharmacology. - 2001. - Vol. 1, suppl 1. - P. 3-31.
  52. Zhang S., Guo Y., Ma Y., Teng Y. Cytotoxin-associated gene-Aseropositive virulent strains of Helicobacter pylori and atherosclerotic disease: a systematic review // Chin Med J. - 2008. - Vol. 121. - P. 946-951.
  53. Franceschi F., Niccoli G., Ferrante G. et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases // Atherosclerosis. - 2009. - Vol. 202. - P. 535-542.
  54. Льнявина В. М. Изменения липидного обмена у больных ишемической болезнью сердца, ассоциированной с дисбиозом кишечника; метаболические эффекты пробиотиков // Автореф. дисс… к. м. н. - СПб, 2009. - 24 с.
  55. Pellicano R., Mazzarello M. G., Morelloni S. et al. Acute myocardial infarction and Helicobacter pylori seropositivity// International Journal of Clinical and Laboratory Research. - 1999. - Vol. 29(4). - P. 141-144.
  56. Fraser A. G., Scragg R. K., Cox B., Jackson R. T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction // Intern Med J. - 2003. - Vol. 33(7). - P. 267-272.
  57. Alkout A. M., Ramsay E. J., Mackenzie D. A. et al. Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease// FEMS Immunology and Medical Microbiology. - 2000. - Vol. 29(4). - P. 271-274.
  58. Liu J, Wang F, Shi S. Helicobacter pylori infection increase the risk of myocardial infarction: a meta-analysis of 26 studies involving more than 20,000 participants. Helicobacter 2014. doi: 10.1111/hel.12188
  59. Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013;62:121-6.
  60. Polyzos SA, Nikolopoulos P, Stogianni A, et al. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study. Arq Gastroenterol 2014;51:261-8.

Full text is published :
Uspenskiy Yu.P., Baryshnikova I.V. HELICOBACTER PYLORI INFECTION AND METABOLIC DISORDERS: IS THE LINK?. Experimental and Clinical Gastroenterology Journal. 2017;143(07):107-114
Read & Download full text

1. North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
2. FSBIS Institute of Experimental Medicine (St. Petersburg, Russian Federation)

Keywords:irritable bowel syndrome,probiotics,autoprobiotics,Еnterococcus faecium,dysbiosis,microbiota

Abstract:The literature review argued that probiotic therapy can increase the effectiveness of standard schemes for management of patients with IBS. Personalized therapy autoprobiotics proved its benefits before treatment of industrial strains. Questions autoprobiotics therapy require further study (the use of other strains of autoprobiotics, the possibility of autoprobiotics of cocktails, expanding the range of nosological forms).

• References total 32 ⇓ :: .
  1. Ивашкин В. Т., Шелыгин Ю. А., Баранская Е. К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. - Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. - 2014. - 24 (2).-C. 92-101.
  2. Шептулин А. А., Кучумова С. Ю. Новое в изучении проблемы синдрома раздраженного кишечника (По материалам докладов 16-й Объединенной Европейской Недели Гастроэнтерологии, Вена, 2008). - Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. - 2009. - 19 (4).-C. 81-5.
  3. Саблин О. А., Ильчишина Т. А. Синдром раздраженного кишечника: обзор римских критериев IV с позиции российских клиницистов. - Экспериментальная и клиническая гастроэнтерология. - 2016.-136 (12).-С.92-101.
  4. Drossman D. A., Hasler W. L. Rome IV -Functional GI disorders: disorders of gut-brain interaction.// Gastroenterology. - 2016. - 150(6). P. 1257-61.
  5. Халиф И. Л., Белоус С. С. Лечение синдрома раздраженного кишечника: равнение на пробиотики.// Справочник поликлинического врача. - 2014.-N 07. - C. 45-49
  6. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management.// J Dig Dis. - 2007. - 8. - P. 2-7
  7. Verdu EF, Collins SM. Irritable bowel syndrome and probiotics: From Rational to Clinical Use. //Curr Opin Gastroenterol. - 2005. - 21(6).-P.697-701.
  8. Boirivant M, Strober W. The mechanism of action of probiotics.// Curr Opin Gastroenterol. - 2007. - 23(6).-P. 679-92.
  9. Halpern, G.M., Prindiville, T. et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial//Am.J.Gastroenterology.-1996.-91.-P.1579-1585.
  10. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Ga-stroenterol Hepatol 2001;13:1143-47.
  11. Sen S, Mullan MM, Parker TJ, et al. Effect of lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.
  12. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacilli and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
  13. A.P.S.Hungin, C. Mulligan et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. http://onlinelibrary.wiley.com/doi/10.1111/apt.12460/full
  14. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008; 32: 147-52
  15. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E. coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009; 47: 209-14.
  16. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57.
  17. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-96.
  18. Simrén M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010; 31: 218-27.
  19. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90
  20. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis dn-173 010 on the health-related quality of life and symptoms in irritable bowel syndromedults in primary care: a multicentre, randomized, double-blind, controlled trial.// Aliment Pharmacol Ther. - 2005. - 26. - P. 475-86.
  21. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
  22. Ушкалова Е. А. Роль пробиотиков в гастроэнтерологии. - Фарматека. - 2007. № 6. - С. 16-23.
  23. Kim H. J., Vazquez Roque M. I., Camilleri M., et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. - Neurogastroenterol Motil. - 2005; 17(5).-Р.687-96.
  24. Bittner A. C., Croffut R. M., Stranahan M. C. Prescriptassist probiotic-prebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. - Clinical Therapeutic, 2005. - 27(6).-Р.755-61.
  25. Корниенко Е. А. Современный подход к коррекции кишечной микробиоты у детей. - Методическое пособие для врачей. - Санкт-Петербург. -2007. - с. 4-10.
  26. Шендеров Б. А. Медицинская микробная экология и функциональное питание. Том I: Микрофлора человека и животных и ее функции. - М.: ГРАНТь, 1998. -288 с.
  27. Hennequin C., Kauffmann-Lacroix C., Jobert A., et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000; 19(1): 16-20
  28. Lherm T., Monet C., Nougiere B. et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients // Intens. Care. Med. - 2002. - V. 28. - P. 797-801.
  29. Marteau P., Gerhardt M. F., Myara A., Bouvier E., Trivin F., Rambaud J. C. Metabolism of bile salts by alimentary bacteria during transit in human small bowel // Microbiol. Ecol. Health Dis. - 1995. - 8. - 1517.
  30. Симаненков В. И., Суворов А. Н., Соловьева О. И. Патент РФ № 2546253. 02.03.2015. Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженного кишечника с использованием этого продукта. 2015. Бюл. № 10
  31. Ермоленко Е. И., Свиридо Д. А., Котылева М. П., Карасева А. Б., Ермоленко К. Д., Соловьева О. И., Симаненков В. И., Суворов А. Н. Коррекция дисбиоза кишечника крыс индигенными рекомбинантными штаммами энтерококков и длительность их персистирования в составе кишечного микробиоценоза// Экспериментальная и клиническая гастроэнтерология.2016.-№ 12. - С. 65-69.
  32. Соловьева О. И., Симаненков В. И. Суворов А. Н. и др. Возможности пробиотической терапии в гастроэнтерологии. - Вестник Санкт-Петербургской МАПО.-2011.-№ 4, том 3.-С.69-81

Full text is published :
Solov’eva O.I., Simanenkov V.I., Suvorov A.N., Ermolenko E.I. et al. THE USE OF PROBIOTICS AND AUTOPROBIOTICS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;143(07):115-120
Read & Download full text

1. Kazan State Medical University (kazan, Russian Federation)

Keywords:microbiota,cytokines,ulcerative colitis,Crohn’s disease,inflammatory bowel diseases

Abstract:The continuous study of the role of genetic factors, intestinal microbiota, and immune system in the pathogenesis of inflammatory bowel diseases is due to the ongoing increase of incidences of ulcerative colitis and Crohn’s disease, unknown etiology, and insufficiently studied pathogenesis of these diseases, as well as insufficient efficiency of existing treatment methods. The role of genetic factors determining predisposition to autoimmune reactions leading to chronic inflammation as well as association of genetic factors and particular composition of intestinal microbiota in pathogenesis of inflammatory bowel diseases are discussed recently. Changes of intestinal microbiome are considered to be one of the triggers of autoimmune inflammation. Violation of recognition of bacterial molecular markers by dendritic cells, leading to activation of Th1, Th2 and Th17 lymphocytes adaptive subpopulations is considered to be the key defect predisposing to inflammatory bowel diseases development. Probably it is the peculiarities of the composition of the intestinal microbiota that can be the cause of chronic autoimmune inflammation induction in inflammatory bowel diseases.

• References total 48 ⇓ :: .
  1. Loddo I, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. Front Immunol. 2015; 6: 551.
  2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142: 46-54.
  3. Legaki E, Gazouli M. Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016; 7(1): 112-125.
  4. Ventham NT, Kennedy NA, Nimmo ER, Satsangi J. Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics. Gastroenterology. 2013; 145(2): 293-308.
  5. Prideaux L, Kang S, Wagner J, et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19 (13): 2906-2918.
  6. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486: 222-227.
  7. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. Journal of Digestive Diseases. 2007; 8: 171-178.
  8. Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012; 61(12): 1686-92.
  9. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991; 100(1): 143-9.
  10. Cantorna MT, McDaniel K, Bora S, et al. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. ExpBiol Med (Maywood). 2014; 239: 1524-1530.
  11. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-17.
  12. Zator ZA, Cantu SM, Konijeti GG, et al. Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti-Tumor Necrosis Factor-alpha Therapy in Inflammatory Bowel Diseases. JPEN J Parenter Enteral Nutr. 2014; 38(3): 3885-91.
  13. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015; 37: 47-55.
  14. Шумилов П. В. Нерешенные вопросы патогенеза воспалительных заболеваний кишечника у детей. Роль пристеночной микрофлоры кишечника. // Педиатрическая фармакология. - 2010. - 5(7). - С. 54-58.
  15. Hugot JP et al. Association of NOD 2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001; 411 (6837): 599-603.
  16. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015; 2015: 505878.
  17. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006; 5778: 1355-1359.
  18. Erickson AR, Cantarel BL, Lamendella R, Darzi Y. Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn’s Disease. PLoS One. 2012; 7(11): e49138.
  19. Полуэктова Е. А., Ляшенко О. С., Шифрин О. С. и соавт. Современные методы изучения микрофлоры желудочно-кишечного тракта человека. // РЖГГК. - 2014. - 24 (2). - C.85-91.
  20. Каштанова Д. А., Егшатян Л. В., Ткачева О. Н. Участие микробиоты кишечника человека в процессах хронического системного воспаления // Клин. микробиол. антимикроб. химиотер. - 2015. - 17(4). - C.310-317.
  21. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing // Nature. 2010; 464(7285): 59-65.
  22. Quigley EMM. Gut Bacteria in Health and Disease. Gastroenterol Hepatol (NY). 2013; 9(9): 560-569.
  23. Бондаренко В. М., Лиходед В. Г. Идеи И. И. Мечникова и современная микроэкология кишечника человека // Журн. микробиол. - 2008. - 5. - С. 23-29.
  24. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during healthand disease. Nature Reviews Immunology. 2009; 9: 313-323.
  25. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer // Nature Reviews Microbiology AOP. 2014 Oct; 12(10): 661-672.
  26. Eckburg PB, Bik EM, Bernstein CN. Diversity of the Human Intestinal Microbial Flora. Science. 2005; 308(5728): 1635-1638.
  27. Mshvildadze M, Neu J. The infant intestinal microbiome: Friend or foe? Early Hum. Dev. 2010; 67-71.
  28. Ткаченко Е. И. Суворова А. Н. Дисбиоз кишечника. Руководство по диагностике и лечению. - СПБ.: ИнформМед, 2009. - 277 с.
  29. Максимова, О. В. Оценка микробиоты кишечника у детей с аллергическими заболеваниями в зависимости от массы тела. - Москва, 2015. - 118 с.
  30. Collado MC, Rautava S, Aakko J, et al. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci. Rep. 2016; 6: 23129.
  31. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. ActaPaediatr. 2009; 98(2): 229-238.
  32. Бочков И. А. Особенности формирования аутомикрофлоры у новорожденных детей в раннем неонатальном периоде (эпидемиологические и микробиологические аспекты). - M.: Автореф. дис. докт. мед.наук.1998. - 38 c.
  33. Kumar M, Babaei P, Ji B, Nielsen J. Human gut microbiota and healthy aging: Recent developments and future prospective. Nutrition Healthy Aging. 2016; 4: 3-16.
  34. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010; 18: 190-195.
  35. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. International Journal of Obesity. 2008; 32(11): 1720-1724.
  36. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. ProcNatlAcadSci U S A. 2011; 108(1): 4578-4585.
  37. Fouhy F, Ross RP, Fitzgerald GF, et al. Composition of the early intestinal microbiota. Gut Microbes. 2012; 3(3): 203-220.
  38. Ивашкин В. Т. и соавт. Рекомендации по диагностике и лечению взрослых пациентов с болезнью Крона. // Рекомендации «Российской гастроэнтерологической ассоциации», ООО «Ассоциация колопроктологов России» и «Общества по изучению воспалительных заболеваний кишечника» при «Ассоциации колопроктологов России». - 2013. - С. 23.
  39. Galvez J. Role of Th17 cells in the Pathogenesis of Human IBD. ISRN Inflammation. 2014; 3: 14.
  40. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317.
  41. MacDonald TT, Monteleone G. Adaptive immunity: Effector and inhibitory cytokine pathways in gut inflammation. In: Inflammatory bowel disease. Eds. Targan SR. et al. 2010; 82-91.
  42. Kobayashi KS, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731-734.
  43. Noble CL, et al. The contribution of OCTN 1/2 variants within the IBD 5 locus to disease susceptibility and severity in Crohn’s disease. Gastroenterology. 2005; 129: 1854-1864.
  44. Miguel J, Sahuquillo A, Agustin IC. Ulcerative Colitis and Microorganisms. Ulcerative Colitis from Genetics to Complications. 2011; 41-62.
  45. Biagi B, Nylund L, Candela M, et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010; 5: 10667.
  46. Sokol H, Pigneur B, Watterlot L, et al. Faecali bacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn‘s disease patients. PNAS. 2008; 105: 16731-6.
  47. Li KY, Wei JP, Gao SY, et al. Fecal microbiota in pouchitis and ulcerative colitis. World Journal of Gastroenterology. 2016; 22(40): 8929-8939.
  48. Vrakas S, Mountzouris KC, Michalopoulos G, et al. Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease. PLoS One. 2017; 12(1): e0170034.

Full text is published :
Danilova N.A., Valeeva A.R., Abdulkhakov S.R. , Skorokhodkina O.V. et al. THE ROLE OF MICROBIOTA IN DEVELOPMENT OF AUTOIMMUNE INFLAMMATION IN INFLAMMATORY BOWEL DISEASES. Experimental and Clinical Gastroenterology Journal. 2017;143(07):121-125
Read & Download full text

1. SM clinic (St. Petersburg, Russian Federation)

Keywords:metabolic syndrome,PPI,adverse events,antiplatelet agents,NSAID,cytochrome P450 CYP2C 19

Abstract:Patients with metabolic syndrome are in a risk group of trombotic complications of various localisation. Firstly it concerns cardiovascular system thus antiplatelet drugs are widely used in order to prevent that. Another frequent problem is locomotor system diseases and chronic pain of other localisation, which compel patients to take NSADs, but taking both antiplatelet agents and NSAID greatly increase risk of emerging the ulcers and gastrointestinal bleeding. To prevent and cure such problems the proton pomp inhibitors (PPI) have worked well, but some of them, in their turn, may reduce the effect of antiplatelet drugs. Despite many researches the final decision on safety of the combination of antiplatelet drugs (tienopiridins?) and PPI hasn’t taken yet.

• References total 96 ⇓ :: .
  1. Берковская М. А., Бутрова С. А. Метаболический синдром как протромбогенное и провоспалительное состояние: влияние терапевтических мероприятий. Ожирение и метаболиз, 2009, № 4.
  2. Нейфельд И. В., Рогожина И. Е., Скупова И. Н., Бобылева И. В. Интегральная оценка системы гемостаза при постменопаузальном метаболическом синдроме. Бюллетень медицинских интернет-конференций, 2012, № 12, т. 2.
  3. Сумеркина В. А., Чулков Вл.С., Чулков В. С. Состояние системы гемостаза у пациентов с метаболическим синдромом. Здоровье и образование в XXI веке, 2014, № 16 (4), С. 85-88.
  4. Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, et al. Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease. BioMed Research International, 2017;2017:6519704. doi:10.1155/2017/6519704.
  5. Paneni F., Cosentino F. Diabetes and Cardiovascular Disease: AGuideto Clinical Management. - Springer International Publishing Switzerland, 2015. DOI 10.1007/978-3-319-17762-5_1.
  6. Perez-Campos-Mayoral L., Pérez-Campos E., Zenteno E., et al. Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP. Diabetol Metab Syndr, 2014 Aug 29;6(1):93. doi: 10.1186/1758-5996-6-93.
  7. Рекомендации по ведению больных с метаболическим синдромом. Клинические рекомендации. М., 2013.
  8. Суслина З. А., Танашян М. М., Ионова В. Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. - М.: Медицинская книга, 2005. - С. 248.
  9. Bhatt D. L., Scheiman J., Abraham N. S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008; 118: 1894-1909; J Am Coll Cardiol, 2008; 52: 1502-17.
  10. Amsterdam E. A., Wenger N. K., Brindis R. G., Casey D. E., et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (published online ahead of print September 23, 2014). Circulation, doi: 10.1161/CIR.0000000000000134.2014 NSTE-ACS Clinical Practice Guidelines.
  11. Deepak T., Giugliano R. P. Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. Am Heart J., 2009 Nov;158(5):695-705. doi: 10.1016/j.ahj.2009.08.023.
  12. Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.
  13. Rydén L, Grant P. J., Anker S. D., Berne C., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2013 Oct;34(39):3035-87. doi: 10.1093/eurheartj/eht108. Epub 2013 Aug 30.
  14. Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med, 2004, 164: 1243-1246. 10.1001/archinte.164.11.1243.
  15. Цурко В. В., Шавловская О. А., Фокина Н. М. НПВП - что изменилось за последние 10 лет? РМЖ, 2014, № 27, с. 1980.
  16. Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ, 1995; 310: 827-830.
  17. Yeomans N. D., Lanas A. I., Talley N. J. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther, 2005; 22: 795-801.
  18. Hansen M. L., Sørensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010; 170: 1433-1441.
  19. Lanas A., García-Rodríguez L.A., Arroyo M. T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut, 2006; 55: 1731-1738.
  20. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ, 2006;333:726. doi: 10.1136/bmj.38947.697558.AE.
  21. Каминный А. И. Терапия антиагрегантами и нестероидными противовоспалительными пре- паратами. Соотношение риска и пользы. Лечащий врач, 2008, № 7, С. 1-6.
  22. Поражения органов пищеварения, индуцированные приемом нестероидных противовоспалительных препаратов. Под ред. А. В. Шаброва, Ю. П. Успенского. - СПб: ИнформМед, 2013.
  23. Зеленская Е. М., Слепухина А. А., Кох Н. В., Апарцин К. А., Лифшиц Г. И. Генетические, патофизиологические и клинические аспекты антиагрегантной терапии (обзор литературы). Фармакогенетика и фармакогеномика, 2015, № 1, с. 12-19.
  24. Serebruany V. L., Steinhubl S. R., Berger P. B. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol, 2005; 95: 1218-1222.
  25. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.
  26. Peters R. J., Mehta S. R., Fox K. A. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 2003; 108: 1682-1687.
  27. Ivert T., Dalén M., Ander C., Stålesen R., et al. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thromb Res, 2017 Jan;149:64-69. doi: 10.1016/j.thromres.2016.11.018. Epub 2016 Nov 21.
  28. De Abajo F. J., Garcia Rodriguez L. A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol, 2001; 1: 1.
  29. Garcia Rodriguez L. A., Hernandez-Diaz S., de Abajo F. J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol, 2001; 52: 563-571.
  30. Kelly J. P., Kaufman D. W., Jurgelon J. M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet, 1996; 348: 1413-1416.
  31. Korte W., Cattaneo M., Chassot P.-G. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease. GTH, ASARI and ESC. Thromb. Haemost, 2011. Vol. 105, № 5. P. 743-749.
  32. Johnson D. A. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist. Rev Cardiovasc Med, 2005; 6, Suppl 4: S 15-22.
  33. Abraham N. S., Castillo D. L., Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther, 2008; 28: 97-106.
  34. Каратеев А. Е., Насонов Е. Л., Яхно Н. Н., Ивашкин В. Т., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015; 9(1):4-23. DOI:10.14412/1996-7012-2015-1-4-23.
  35. http://antitromb.ru/?news=кангрелор-не-будет-в-ближайшее-время-п- сообщение об отсутствии кангрелора на российском рынке в ближайшем будущем.
  36. Официальная инструкция к препарату «Плавикс» на территории РФ.
  37. Cresci S., Depta J. P., Lenzini P. A., Li A. Y., et al. Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation: Cardiovascular Genetics, 2014; DOI: 10.1161/CIRCGENETICS.113.000303.
  38. Kazui М., Nishiya Y, Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug. Metab. Dispos, 2010, Vol. 38, p. 92-99.
  39. Ma TKW, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol, 2011;72(4):697-706.
  40. Diener H.-C., Bogousslavsky J., Brass L. M., et al. On behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc. Dis, 2004; 77: 253-261.
  41. Kolh P., Windecker S., Alfonso F., Collet J. P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg, 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.
  42. Bhatt D. L., Fox K. A.A., Hacke W. et al. For the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006; 354: 1706-1717.
  43. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, Vol. 345, p. 494-502.
  44. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45?852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005. Vol. 366. P. 1607-1612.
  45. The ACTIVE Investigators (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 360: 2066-78.
  46. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med, 2001. Vol. 345. P. 494-502.
  47. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology, 2014;147:784-92. doi: 10.1053/j.gastro.2014.06.007.
  48. Ивашкин В. Т., Шептулин А. А., Маев И. В., Баранская Е. К., Трухманов А. С., Лапина Т. Л. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. РЖГГК, 2014;19(6):89-94.
  49. Российские рекомендации. ВНОК. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Кардиоваскулярная терапия и профилактика, 2007; тр.: 415-500.
  50. O’Gara P.T., Kushner F. G., Ascheim D. D., Casey D. E., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013 Jan 29;127(4):529-55. doi: 10.1161/CIR.0b013e3182742c84. Epub 2012 Dec 17.
  51. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика, 2011; 10 (6), прил. 2.
  52. Chan F. K., Ching J. Y., Hung L. C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005; 352: 238-244.
  53. Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver, 2014 Jul;8(4):371-9. doi: 10.5009/gnl.2014.8.4.371. Epub 2013 Dec 24.
  54. Oh Yuong Lee, Dae-Hwan Kang, Dong Ho Lee, et al. A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch. Pharm. Res, 2014, vol. 37, p. 1308-1316.
  55. Jan C Becker, Wolfram Domschke, Thorsten Pohle. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. Br J Clin Pharmacol, 2004 Dec; 58(6): 587-600.
  56. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut, 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
  57. Искаков Б. С., Кадирова Ф., Абдилова Д., Амзеева Т., и др. Гастродуоденальные риски антиагрегантной терапии при остром инфаркте миокарда. International Scientific and Practical Conference “WORLD SCIENCE”, 2015, № 4(4), Vol.2.
  58. Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology, 2011;141:71-9. doi: 10.1053/j.gastro.2011.03.049.
  59. Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis?. Int J Clin Pharmacol Ther, 2009;47:1-10. doi: 10.5414/CPP47001.
  60. Kim HK, Kim JI, Kim JK, Han JY, et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci, 2007;52(8):1776-82.
  61. Мороз Е. В., Каратеев А. Е. Pебамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология, 2016; 10(4):97-105.
  62. Jhun J, Kwon J-E, Kim S-Y, et al. Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PLoS ONE, 2017;12(2): e0171674. doi:10.1371/journal.pone.0171674.
  63. Драпкина О. М., Корнеева О. Н. Поражения тонкой кишки при применении нестероидных противовоспалительных препаратов и антитромбоцитарной терапии. Подходы к профилактике и лечению. Терапевтический архив, 2016;88(12): 133-139.
  64. Berger J. S., Stebbins A., Granger C. B. et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation, 2008; 117: 192-199.
  65. James M Scheiman. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther, 2013; 15(Suppl 3): S 5.
  66. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M., et al. CYP2C 19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol, 2012 Sep; 68(9): 1267-1274.
  67. Wedemeyer RS 1, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0.
  68. Бордин Д. С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ?. Медицинский альманах, 2010, № 1(10) март, с. 127-130.
  69. Würtz M, Grove E. L. Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Adv Exp Med Biol, 2017;906:325-350.
  70. Zou D., Goh KL. An East Asian Perspective on the Interaction between Proton Pump Inhibitors and Clopidogrel. J Gastroenterol Hepatol, 2016 Dec 26. doi: 10.1111/jgh.13712. (Epub ahead of print).
  71. Ших Е. В., Сычев Д. А. Безопасность пантопразола с позиций лекарственного взаимодействия. РЖГГК, 2012, т. 22, № 5, с. 4-12.
  72. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther, 2011;89:65-74.
  73. Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y 12 inhibition: results of the randomized DOSAPI study. Eur J Clin Pharmacol, 2014;70:1049-1057.
  74. Frelinger AL, 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol, 2012;59:1304-1311.
  75. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol, 2008;48:475-484.
  76. Qi F., Zhu L, Li N., Ge T., et al. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents, 2017 Apr;49(4):403-409. doi: 10.1016/j.ijantimicag.2016.11.025. Epub 2017 Jan 31.
  77. Goodman SG, Clare R, Pieper KS, et al. Platelet Inhibition and Patient Outcomes Trial Investigators: association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation, 2012;125:978-986.
  78. Niu Q., Wang Z, Zhang Y, Wang J, et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647. (Epub ahead of print).
  79. Weisz G., Smilowitz N. R., Kirtane A. J., Rinaldi M. J., et al. Proton pump inhibitors, platelet reactivity, and cardiovascular outcomes after drug-eluting stents in clopidogrel-treated patients: The ADAPT-DES study. Circ. Cardiovasc. Interv, 2015;8: e001952.
  80. Harvey A., Modak A., Dery U., Roy M., et al. Changes in CYP2C 19 enzyme activity evaluated by the ((13) C)-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J. Breath Res, 2016;10:017104. doi: 10.1088/1752-7155/10/1/017104.
  81. Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Safe, 2016;15:223-36. doi: 10.1517/14740338.2016.1128413.
  82. Vaduganathan M., Cannon C. P., Cryer B. L., Liu Y., et al. Efficacy and safety of proton-pump inhibitors in high -risk cardiovascular subsets of the COGENT trial. Am. J. Med, 2016;129:1002-1005. doi: 10.1016/j.amjmed.2016.03.042.
  83. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009;374:989-997.
  84. Melloni C., Washam J. B., Jones W. S., Halim S. A., Hasselblad V., Mayer S. B., Heidenfelder B. L., Dolor R. J. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: Systematic review. Circ. Cardiovasc. Qual. Outcomes, 2015;8:47-55. doi: 10.1161/CIRCOUTCOMES.114.001177.
  85. Sherwood M. W., Melloni C., Jones W. S., Washam J. B. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc, 2015;4: e002245/.
  86. Levine G. N., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
  87. Cardoso RN, Benjo AM, DiNicolantonio JJ, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart, 2015;2 doi: 10.1136/openhrt-2015-000248.
  88. Scarpignato C., Gatta L., Zullo A., Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med, 2016; 14: 179.
  89. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes, 2012;5:680-688.
  90. Goodman S.G1., Clare R., Pieper K. S., Nicolau J., et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Circulation, 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18.
  91. Medication Guide Plavix® (PLAV-iks) (clopidogrel bisulfate) tablets.
  92. Mistakes in the use of PPIs and how to avoid them. https://www.ueg.eu/education/latest-news/article/article/mistakes-in-alcoholic-liver-disease-and-how-to-avoid-them-copy-1/.
  93. Маев И. В., Самсонов А. А., Годило-Годлевский В.А., Андреев Д. Н., Дичева Д. Т. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогреля при их совместном приеме. Клиническая медицина, 2013, № 5, С. 15-21.
  94. Guérin A., Mody R., Carter V., Ayas C. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. PLoS One, 2016 Jan 4;11(1): e0145504. doi: 10.1371/journal.pone.0145504. eCollection 2016.
  95. Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res, 2011;128:458-462.
  96. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J, 2013;34:1708-1713.

Full text is published :
Edemskaia M.A. SAFETY ASPECTS OF ANTIPLATELETS THERAPY OF PATIENTS WITH METABOLIC SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;143(07):126-134
Read & Download full text